Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.31 and traded as high as $1.48. Cortexyme shares last traded at $1.40, with a volume of 44,182 shares trading hands.
Cortexyme Trading Up 0.7 %
The stock has a market capitalization of $42.51 million, a PE ratio of -0.47 and a beta of 1.40. The firm has a 50 day moving average of $1.71 and a two-hundred day moving average of $1.31.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- Insider Trading – What You Need to Know
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Which Wall Street Analysts are the Most Accurate?
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What is the Australian Securities Exchange (ASX)
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
